

DAFTAR PUSTAKA

Abediazar, S. *et al.* (2019) ‘Serum levels of CXCL10 and vitamin D in patients with lupus nephritis’, *Iranian Journal of Kidney Diseases*, 13(6), pp. 380–388.

Abujam, B., Cheekatla, S. S. and Aggarwal, A. (2013) ‘Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis’, *Lupus*, 22(6), pp. 614–623. doi: 10.1177/0961203313484977.

Aga Lewelt (2015) ‘乳鼠心肌提取 HHS Public Access’, *Physiology & behavior*, 176(3), pp. 139–148. doi: 10.1016/j.physbeh.2017.03.040.

Ameer, M. A. *et al.* (2022) ‘An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management’, *Cureus*, 14(10). doi: 10.7759/cureus.30330.

Annamayra, A. *et al.* (2020) ‘The molecular mechanism of corticosteroids for Systemic Lupus Erythematosus Patient’s treatment and its adverse effects’, *Systematic Reviews in Pharmacy*, 11(2), pp. 249–254. doi: 10.5530/srp.2020.2.38.

Antonelli, A. *et al.* (2014) ‘Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases’, *Autoimmunity Reviews*. Elsevier B.V., 13(3), pp. 272–280. doi: 10.1016/j.autrev.2013.10.010.

Aringer, M. *et al.* (2019) ‘2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus’, *Arthritis and Rheumatology*, 71(9), pp. 1400–1412. doi: 10.1002/art.40930.

Arora, S., Isenberg, D. A. and Castrejon, I. (2020) ‘Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage’, *Arthritis Care and Research*, 72(S10), pp. 27–46. doi: 10.1002/acr.24221.

Badsha, H. and Edwards, C. J. (2003) ‘Intravenous pulses of methylprednisolone for systemic lupus erythematosus’, *Seminars in Arthritis and Rheumatism*, 32(6), pp. 370–377. doi: 10.1053/sarh.2002.50003.

Bazsó, A. *et al.* (2015) ‘The importance of glucocorticoid receptors in systemic lupus erythematosis. A systematic review’, *Autoimmunity Reviews*. Elsevier B.V., 14(4), pp. 349–351. doi: 10.1016/j.autrev.2014.12.007.

Bruce, I. N. *et al.* (2015) ‘Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort’, *Annals of the Rheumatic Diseases*, 74, pp. 1706–1713. doi: 10.1136/annrheumdis-2013-205171.

Brunner, H. I. *et al.* (2003) 'Item Weightings for the Systemic Lupus International Collaborating Clinics / American College of Rheumatology Disease Damage Index Using Rasch Analysis Do Not Lead to an Important Improvement', *Journal of Rheumatology*, 30, pp. 292–298.

Buckner, C. A. *et al.* (2016) 'We are IntechOpen , the world ' s leading publisher of Open Access books Built by scientists , for scientists TOP 1 %', *Intech*, 11(tourism), p. 13. Available at: <https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics>.

Buttgereit, F. *et al.* (2002) 'Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology', *Annals of the Rheumatic Diseases*, 61(8), pp. 718–722. doi: 10.1136/ard.61.8.718.

Cardoso, C. R. L. *et al.* (2008) 'Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: A cohort study', *Lupus*, 17(11), pp. 1042–1048. doi: 10.1177/0961203308093829.

Catalina, M. D. *et al.* (2020) 'The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus', *Journal of Autoimmunity*. Elsevier, 110(November), p. 102359. doi: 10.1016/j.jaut.2019.102359.

Chan, W. K. Y. (2023) 'A Review on Childhood-onset Systemic Lupus Erythematosus', *RPN.000668*, 7(4), pp. 5–8. doi: 10.31031/RPN.2023.07.000668.

Cheng Wang K, Huie Liu P, Hiu Yu, K, Jin Ng C, Fa Chiu T, Y. C. S. (2017) 'Is initial C-reactive protein level associated with corticosteroid use in lupus erythematosus patients during a bacterial infection episode ?' *Immunology Letters* 185, pp. 84–89.

Condon, M. B. *et al.* (2013) 'Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids', *Annals of the Rheumatic Diseases*, 72(8), pp. 1280–1286. doi: 10.1136/annrheumdis-2012-202844.

Corsini, E. *et al.* (2018) 'Chemical-induced contact allergy: from mechanistic understanding to risk prevention', *Archives of Toxicology*. Springer Berlin Heidelberg, 92(10), pp. 3031–3050. doi: 10.1007/s00204-018-2283-z.

Czaja, A. J. (2014) 'Alimentary Pharmacology and Therapeutics Review article : chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets', (May). doi: 10.1111/apt.12825.

Davidson, A. (2012) 'The rationale for BAFF inhibition in systemic lupus erythematosus', *Current Rheumatology Reports*, 14(4), pp. 295–302. doi: 10.1007/s11926-012-0258-2.

Demircin, G. *et al.* (2008) 'Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis', *Renal Failure*, 30(6), pp. 603–609. doi: 10.1080/08860220802132171.

Dominguez-gutierrez, P. R. *et al.* (2012) 'Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients', pp. 1–3.

Dominguez-gutierrez, P. R. *et al.* (2014) 'Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone , mycophenolate mofetil , or hydroxychloroquine , except in a high STAT1 subset', *Arthritis Research & Therapy*. *Arthritis Research & Therapy*, 16(1), pp. 1–15. doi: 10.1186/ar4451.

Duan, J. H. *et al.* (2016) 'Expression of BAFF and BR3 in patients with systemic lupus erythematosus', *Brazilian Journal of Medical and Biological Research*, 49(3), pp. 3–7. doi: 10.1590/1414-431X20154853.

Duffau, P. *et al.* (2010) 'Platelet CD154 potentiates interferon- α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus', *Science Translational Medicine*, 2(47). doi: 10.1126/scitranslmed.3001001.

El-gohary, A. *et al.* (2016) 'Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Nephritis', *Journal of Clinical Laboratory Analysis*, 30, pp. 1135–1138. doi: 10.1002/jcla.21993.

Elhefny, A. A. M. *et al.* (2019) 'Hazards of pulse steroid use in a cohort of Egyptian lupus nephritis patients', *Egyptian Rheumatologist*. *Egyptian Society of Rheumatic Diseases*, 41(4), pp. 277–281. doi: 10.1016/j.ejr.2018.12.001.

Enríquez-Merayo, E. and Cuadrado, M. J. (2023) 'Steroids in Lupus: Enemies or Allies', *Journal of Clinical Medicine*, 12(11), pp. 1–9. doi: 10.3390/jcm12113639.

Enriquez Merayo, E. *et al.* (2018) 'Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?', *Expert Review of Clinical Immunology*. Taylor & Francis, 14(11), pp. 877–879. doi: 10.1080/1744666X.2018.1527219.

Fanouriakis, A. *et al.* (2019) '2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus', *Annals of the Rheumatic Diseases*, 78(6), pp. 736–745. doi: 10.1136/annrheumdis-2019-215089.

Fayyaz, A. *et al.* (2015) 'Haematological manifestations of lupus', *Lupus Science and Medicine*, 2(1). doi: 10.1136/lupus-2014-000078.

Fragoso-Loyo, H. *et al.* (2013) 'Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus', *Rheumatology (United Kingdom)*, 52(12), pp. 2218–2222. doi: 10.1093/rheumatology/ket294.

Fresneda Alarcon, M., McLaren, Z. and Wright, H. L. (2021) 'Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O.', *Frontiers in Immunology*, 12(March). doi: 10.3389/fimmu.2021.649693.

Fung, W. A., Su, J. and Touma, Z. (2017) 'Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis : Results from a Single Lupus Cohort', *BioMed Research International*, 2017.

Furie, R. *et al.* (2011) 'A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus', *Arthritis and Rheumatism*, 63(12), pp. 3918–3930. doi: 10.1002/art.30613.

Gao, J. *et al.* (2020) 'Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases', *Mediators of Inflammation*, 2020. doi: 10.1155/2020/6194864.

Gauthier, M. *et al.* (2017) 'Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias', *JCI Insight*, 2(13), pp. 1–17. doi: 10.1172/jci.insight.94580.

Geneva-Popova, M. G. *et al.* (2022) 'A Study of IFN- α -Induced Chemokines CCL2, CXCL10 and CCL19 in Patients with Systemic Lupus Erythematosu', *Life*, 12(2). doi: 10.3390/life12020251.

Gensous, N. *et al.* (2017) 'Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review', *Arthritis Research & Therapy*. *Arthritis Research & Therapy*, 19(1), p. 238. doi: 10.1186/s13075-017-1442-6.

Goilav, B. and Putterman, C. (2016) *HHS Public Access*. doi: 10.1016/j.semnephrol.2015.08.005.The.

Green, D. S., Young, H. A. and Valencia, J. C. (2017) 'Current prospects of type II interferon γ signaling & autoimmunity', *Journal of Biological Chemistry*, 292(34), pp. 13925–13933. doi: 10.1074/jbc.R116.774745.

Gustavson, D. E. and Miyake, A. (2016) '乳鼠心肌提取 HHS Public Access', *Cognition Emotion Journal*, 30(7), pp. 1289–1303. doi: 10.1016/j.semarthrit.2019.03.010.Glucocorticoids.

Han, B. K. *et al.* (2020) 'Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus', *Lupus Science and Medicine*, 7(1), pp. 1–6. doi: 10.1136/lupus-2020-000382.

Hannah, J. R. and Cruz, D. P. D. (2019) 'Pulmonary Complications of Systemic Lupus Erythematosus', *Seminars in Respiratory and Critical Care Medicine*, 40(2), pp. 227–234.

Hari pankaj (2004) 'Indian Pediatrics', *indian Pediatrics*. New Delhi: indian

Pediatrics 2004, 41, pp. 993–1000. Available at: <http://indianpediatrics.net/may2008/may-410-412.htm>.

He, Z. *et al.* (2022) ‘Comprehensive analysis of epigenetic modifications and immune-cell infiltration in tissues from patients with systemic lupus erythematosus’, *Epigenomics*, 14(2), pp. 81–100. doi: 10.2217/epi-2021-0318.

Hessels, A. C. *et al.* (2019) ‘Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11 β -hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor’, *Rheumatology (United Kingdom)*, 58(3), pp. 447–454. doi: 10.1093/rheumatology/key319.

Hosmer and Lemeshow (2013) ‘Epdf.Pub_Applied-Logistic-Regression-Wiley-Series-in-Probab.Pdf’.

Hrycek, E. *et al.* (2013) ‘Serum levels of selected chemokines in systemic lupus erythematosus patients’, *Rheumatology International*, 33(9), pp. 2423–2427. doi: 10.1007/s00296-012-2393-5.

Hu Xiaoyu, Ping Li Wai, Meng Charis, I. L. B. (2003) ‘Inhibition of IFN-gamma Signaling by Glucocorticoid’, *The Journal of Immunology*, 170, pp. 4833–4839.

Illescas-Montes, R. *et al.* (2019) ‘Infectious processes and systemic lupus erythematosus’, *Immunology*, 158(3), pp. 153–160. doi: 10.1111/imm.13103.

Isenberg, D. A., Morrow, W. J. W. and Snaith, M. L. (1982) ‘Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus’, *Annals of the Rheumatic Diseases*, 41(4), pp. 347–351. doi: 10.1136/ard.41.4.347.

J.A., R. *et al.* (2018) ‘Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations’, *Arthritis Research and Therapy*. Arthritis Research & Therapy, pp. 1–10.

Jara, L. J. *et al.* (2005) ‘methylprednisolone in severe neurological manifestations in’, pp. 620–625. doi: 10.1136/ard.2004.025528.

Ji, L. *et al.* (2022) ‘Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal . A analysis systematic review and meta- -’. doi: 10.1136/lupus-2021-000603.

Kamhieh-Milz, J. *et al.* (2018) ‘Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP)’, *Clinical Immunology*. Elsevier Inc, 188, pp. 74–80. doi: 10.1016/j.clim.2017.12.010.

Kandane-Rathnayake, R. *et al.* (2021) ‘Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: A longitudinal, multinational study’, *Rheumatology (Bulgaria)*, 60(11), pp. 5185–5193. doi: 10.1093/rheumatology/keab217.

Kaplan, M. J. (2011) ‘Neutrophils in the pathogenesis and manifestations of SLE.’,

Nature reviews. Rheumatology. United States, 7(12), pp. 691–699. doi: 10.1038/nrrheum.2011.132.

Khalifa.A.S, T. K. . (1993) ‘No Tit.צתקל’, *Acta Haematol*, 90, pp. 125–129. Available at: <https://www.ptonline.com/articles/how-to-get-better-mfi-results>.

Khan, M. A. H. *et al.* (2019) ‘Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice’, *Frontiers in Pharmacology*, 10(MAY), pp. 1–10. doi: 10.3389/fphar.2019.00512.

Kong, K. O. *et al.* (2009) ‘Enhanced expression of interferon-inducible protein- 10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus’, pp. 134–140. doi: 10.1111/j.1365-2249.2009.03880.x.

Koupenova, M. *et al.* (2018) ‘Circulating platelets as mediators of immunity, inflammation, and thrombosis’, *Circulation Research*, 122(2), pp. 337–351. doi: 10.1161/CIRCRESAHA.117.310795.

Lambers, W. M. *et al.* (2021) ‘Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus’, *Journal of Rheumatology*, 48(6), pp. 847–851. doi: 10.3899/jrheum.200726.

Lee, J. S. *et al.* (2018) ‘Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea’, *Medicine (United States)*, 97(26), pp. 1–5. doi: 10.1097/MD.00000000000011138.

Li, Y. *et al.* (2015) ‘Behavioral deficits are accompanied by immunological and neurochemical changes in a mouse model for neuropsychiatric lupus (NP-SLE)’, *International Journal of Molecular Sciences*, 16(7), pp. 15150–15171. doi: 10.3390/ijms160715150.

Liu, J., Zhang, X. and Cao, X. (2022) ‘Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications’, *Journal of Autoimmunity*. Elsevier Ltd, 132(June), p. 102856. doi: 10.1016/j.jaut.2022.102856.

Liu, M. *et al.* (2018) ‘Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity’, *Clinical Rheumatology*. Clinical Rheumatology, 37(10), pp. 2675–2684. doi: 10.1007/s10067-018-4138-7.

Liu, Y. *et al.* (2022) ‘Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review’, *Frontiers in Cell and Developmental Biology*, 10(September), pp. 1–11. doi: 10.3389/fcell.2022.998328.

Ma, K. *et al.* (2019) ‘Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus’, *International Journal of Molecular Sciences*, 20(23). doi:

10.3390/ijms20236021.

Magro-Checa, C. *et al.* (2016) ‘Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives’, *Drugs*, 76(4), pp. 459–483. doi: 10.1007/s40265-015-0534-3.

Man, B. L., Mok, C. C. and Fu, Y. P. (2014) ‘Neuro-ophthalmologic manifestations of systemic lupus erythematosus: A systematic review’, *International Journal of Rheumatic Diseases*, 17(5), pp. 494–501. doi: 10.1111/1756-185X.12337.

Mathian, A. *et al.* (2015) ‘Regulatory T cell responses to high-dose methylprednisolone in active systemic lupus erythematosus’, *PLoS ONE*, 10(12), pp. 1–17. doi: 10.1371/journal.pone.0143689.

Mejía-Vilet, J. M. and Ayoub, I. (2021) ‘The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug’, *Frontiers in Medicine*, 8(February), pp. 1–11. doi: 10.3389/fmed.2021.622225.

Migita, K. *et al.* (2018) ‘Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis’, *Medicine (United States)*, 97(50), pp. 1–9. doi: 10.1097/MD.00000000000013450.

Mikdashi, J. and Nived, O. (2015) ‘Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research’, *Arthritis Research & Therapy*. *Arthritis Research & Therapy*, pp. 1–10. doi: 10.1186/s13075-015-0702-6.

Mikolajczyk, T. P. *et al.* (2021) ‘Pharmacology & Therapeutics Role of inflammatory chemokines in hypertension’, 223. doi: 10.1016/j.pharmthera.2020.107799.

Möckel, T. *et al.* (2021) ‘B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)’, *Autoimmunity Reviews*, 20(2), pp. 10–17. doi: 10.1016/j.autrev.2020.102736.

Morais, S. A., Vilas Boas, A. and Isenberg, D. A. (2015) ‘B-cell survival factors in autoimmune rheumatic disorders’, *Therapeutic Advances in Musculoskeletal Disease*, 7(4), pp. 122–151. doi: 10.1177/1759720X15586782.

Moretti, M. *et al.* (2023) ‘Systemic lupus erythematosus: one year in review 2023’, *Clinical and Experimental Rheumatology*, 41(4), pp. 765–773. doi: 10.55563/clinexprheumatol/zf4daj.

Mu, Q. *et al.* (2017) ‘Control of lupus nephritis by changes of gut microbiota’. *Microbiome*, pp. 1–12. doi: 10.1186/s40168-017-0300-8.

Murayama, M. A. *et al.* (2023) ‘Chemokines and chemokine receptors as promising targets in rheumatoid arthritis’, (February), pp. 1–17. doi:

10.3389/fimmu.2023.1100869.

Nagai, T. *et al.* (2005) ‘Anti – Ribosomal P Protein Antibody in Human Systemic Lupus Erythematosus Up-Regulates the Expression of Proinflammatory Cytokines by Human Peripheral Blood Monocytes’, *52(3)*, pp. 847–855. doi: 10.1002/art.20869.

Narváez, J. *et al.* (2018) ‘Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort’. *Arthritis Research & Therapy*, 8, pp. 1–10.

Navarra, S. V. *et al.* (2011) ‘Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial’, *The Lancet*. Elsevier Ltd, 377(9767), pp. 721–731. doi: 10.1016/S0140-6736(10)61354-2.

Netti, G. S. *et al.* (2019) ‘Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy’, *Journal of Immunology Research*, 1, pp. 1–12. doi: 10.1155/2019/8483650.

Nishioji, K. *et al.* (2001) ‘Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes’, *Clin Exp Immunol*, 123(2), pp. 271–279.

Nived, O. *et al.* (2002) ‘High predictive value of the Systemic Lupus International Collaborating Clinics / American College of Rheumatology damage index for survival in systemic lupus erythematosus’, *Journal of Rheumatology*, 29(7), pp. 1398–1400.

Nomura, A. *et al.* (2019) ‘Unique primed status of microglia under the systemic autoimmune condition of lupus-prone mice’, *Arthritis Research and Therapy*. *Arthritis Research & Therapy*, 21(1), pp. 1–17. doi: 10.1186/s13075-019-2067-8.

Ocejo, A. and Correa, R. (2023) ‘Methylprednisolone.’, in. Treasure Island (FL).

Odler, B. *et al.* (2017) ‘CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients.’, *Lupus*. England, 26(6), pp. 572–579. doi: 10.1177/0961203316668418.

Ohmura, K. (2021) ‘Which is the best SLE activity index for clinical trials?’, *Modern Rheumatology*. Taylor & Francis, 31(1), pp. 20–28. doi: 10.1080/14397595.2020.1775928.

Oke, V. *et al.* (2017) ‘IFN- λ 1 with Th17 axis cytokines and IFN- α define different subsets in systemic lupus erythematosus (SLE)’, *Arthritis Research and Therapy*. *Arthritis Research & Therapy*, 19(1), pp. 1–12. doi: 10.1186/s13075-017-1344-7.

Oku, K. and Atsumi, T. (2018) ‘Systemic lupus erythematosus: nothing stale her infinite variety’, *Modern Rheumatology*. Taylor & Francis, 28(5), pp. 758–765. doi:

10.1080/14397595.2018.1494239.

Oon, S., Wilson, N. J. and Wicks, I. (2016) 'Targeted therapeutics in SLE : emerging strategies to modulate the interferon pathway'. Nature Publishing Group, 5(5), pp. e79-10. doi: 10.1038/cti.2016.26.

P, J. E., Idha, A. and Suryana, B. P. P. (2015) 'Megadose Methylprednisolone On Total Lymphocyte Count and Disease Activity In Systemic Lupus Erythematosus (SLA)', 51(1), pp. 40–44.

Pan, L. *et al.* (2020) 'Immunological pathogenesis and treatment of systemic lupus erythematosus', *World Journal of Pediatrics*. Childrens Hospital, Zhejiang University School of Medicine, 16(1), pp. 19–30. doi: 10.1007/s12519-019-00229-3.

Perhimpunan Reumatologi Indonesia (2018) *Pedoman Diagnosis dan Pengelolaan Gout Rekomendasi Perhimpunan Reumatologi Indonesia*.

Porta, S. *et al.* (2020) 'Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues', *Journal of Clinical Medicine*, 9(9), pp. 1–13. doi: 10.3390/jcm9092709.

Puapatanakul, P., Chansritrakul, S. and Susantitaphong, P. (2019) 'Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis : A Systematic Review and Meta-Analysis', *Int J Mol Sci.*, 20, pp. 1–14.

Qian, H. *et al.* (2020) 'Associations of Platelet Count with Inflammation and Response to Anti-TNF- α Therapy in Patients with Ankylosing Spondylitis', *Frontiers in Pharmacology*, 11(November), pp. 1–10. doi: 10.3389/fphar.2020.559593.

Qin, B. *et al.* (2015) 'Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) were Useful Markers in Assessment of Inflammatory Response and Disease Activity in SLE patients', 7595(September). doi: 10.3109/14397595.2015.1091136.

Ramsey-goldman, R. *et al.* (2017) 'Cell-bound complement activation products in SLE', *Lupus Science and Medicine*, pp. 1–8. doi: 10.1136/lupus-2017-000236.

Rekomendasi Perhimpunan Reumatologi Indonesia (2019) 'Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik ISBN Perhimpunan Reumatologi Indonesia', in, p. 9.

Riedel, J. H. *et al.* (2023) 'Glucocorticoids target the CXCL9/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury', *JCI Insight*, 8(1). doi: 10.1172/jci.insight.160251.

Rivera, M. F. C. and Dans, L. F. (2022) 'Systemic Lupus Erythematosus in Filipino

Children: A 10-year Retrospective Analysis of Mortality, Morbidity and Survival', *Acta Medica Philippina*, 56(9), pp. 98–106. doi: 10.47895/amp.v56i9.5380.

Rose, T. *et al.* (2013) 'IFN α and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.', *Annals of the rheumatic diseases*. England, 72(10), pp. 1639–1645. doi: 10.1136/annrheumdis-2012-201586.

Rovin, B. H. *et al.* (2005) 'Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy', *Kidney International*, 68(2), pp. 747–759. doi: 10.1016/s0085-2538(15)50895-8.

Rovin, B. H. *et al.* (2019) 'A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis', *Kidney International*, 95(1), pp. 219–231. doi: 10.1016/j.kint.2018.08.025.

Ruiz-Irastorza, G. *et al.* (2014) 'Prednisone in lupus nephritis: How much is enough?', *Autoimmunity Reviews*. Elsevier B.V., 13(2), pp. 206–214. doi: 10.1016/j.autrev.2013.10.013.

Ruiz-Irastorza, G. *et al.* (2016) 'Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus', *Clinical and Experimental Rheumatology*, 34(3), pp. 466–472.

Ruiz-Irastorza, G. *et al.* (2019) 'Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts', *Autoimmunity Reviews*. Elsevier, 18(9), p. 102359. doi: 10.1016/j.autrev.2019.102359.

Ruiz-Irastorza, G. (2020) 'Can we effectively treat lupus and reduce the side-effects of glucocorticoids?', *The Lancet Rheumatology*. Elsevier Ltd, 2(1), pp. e3–e5. doi: 10.1016/S2665-9913(19)30132-8.

Ruiz-Irastorza, G. *et al.* (2020) 'Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus', *Lupus*, 29(10), pp. 1155–1167. doi: 10.1177/0961203320930099.

Ruiz-Irastorza, G., Danza, A. and Khamashta, M. (2018) 'Glucocorticoid use and abuse in SLE', *Rheumatology (United Kingdom)*, 51(7), pp. 1145–1153. doi: 10.1093/rheumatology/ker410.

Sahebari Maryam, Rezaieyazdi, Z. *et al.* (2023) 'Expression pattern of glucocorticoid receptor alpha gene and associations with clinicolaboratory features in patients with systemic lupus erythematosus', *Caspian Journal of Internal Medicine* 2023;14(3); 2023(3), pp. 470–478. doi: 10.22088/cjim.14.3.470.

Schäfer, V. S. *et al.* (2018) 'Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with

clinical and laboratory parameters of disease activity', *Clinical Rheumatology*. *Clinical Rheumatology*, 37(7), pp. 1835–1844. doi: 10.1007/s10067-018-4093-3.

Scofield RH (2020) 'Systemic Lupus Erythematosus (SLE) Genetics What to Read Next on Medscape', *Genomic Medicine*.

Seet, D. *et al.* (2021) 'Cognitive Dysfunction in Systemic Lupus Erythematosus: Immunopathology, Clinical Manifestations, Neuroimaging and Management', *Rheumatology and Therapy*. Springer Healthcare, 8(2), pp. 651–679. doi: 10.1007/s40744-021-00312-0.

Sellam, J. *et al.* (2007) 'Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus', *Annals of the Rheumatic Diseases*, 66(6), pp. 790–797. doi: 10.1136/ard.2006.065656.

Shaquara, M. *et al.* (2016) 'Membrane-bound glucocorticoid receptors on distinct nociceptive neurons as potential targets for pain control through rapid non-genomic effects', *Neuropharmacology*, 111, pp. 1–13. doi: 10.1016/j.neuropharm.2016.08.019.

Shiozawa, F. *et al.* (2004) 'Research article Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL / lpr mice', *Arthritis Research & Therapy*, 6(1), p. R 78. doi: 10.1186/ar1029.

Shobha, V. *et al.* (2023) 'Severe thrombocytopenia is associated with high mortality in systemic lupus erythematosus — analysis from Indian SLE Inception cohort for Research (INSPIRE)', *Clinical Rheumatology*. Springer International Publishing, (0123456789). doi: 10.1007/s10067-023-06641-5.

Sim, T. M., Mak, A. and Tay, S. H. (2022) 'Insights into the role of neutrophils in neuropsychiatric systemic lupus erythematosus: Current understanding and future directions', *Frontiers in Immunology*, 13(August), pp. 1–15. doi: 10.3389/fimmu.2022.957303.

Sinha, A. and Bagga, A. (2008) 'Pulse Steroid Therapy', *Indian Journal of Pediatrics*, 75, pp. 1057–1066.

Smulski, C. R. and Eibel, H. (2018) 'BAFF and BAFF-receptor in B cell selection and survival', *Frontiers in Immunology*, 9(OCT), pp. 1–10. doi: 10.3389/fimmu.2018.02285.

Stohl, W. (2017) 'Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)', *Expert Review of Clinical Immunology*. Taylor & Francis, 13(6), pp. 623–633. doi: 10.1080/1744666X.2017.1291343.

Stojan, G. and Petri, M. (2017) 'HHS Public Access', *Curr Treatm Opt Rheumatol*, 3(3), pp. 164–172. doi: 10.1007/s40674-017-0069-8.The.

Strehl, C. *et al.* (2019) ‘Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System’, *Frontiers in immunology*, 10(July), p. 1744. doi: 10.3389/fimmu.2019.01744.

Suso, J. P. *et al.* (2018) ‘Profile of BAFF and its receptors’ expression in lupus nephritis is associated with pathological classes’, *Lupus*, 27(5), pp. 708–715. doi: 10.1177/0961203317739132.

Thanou, A. *et al.* (2019) ‘Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures’, *Lupus Science and Medicine*, 6(1), pp. 1–6. doi: 10.1136/lupus-2019-000365.

Touma, Z. and Gladman, D. D. (2017) ‘Current and future therapies for SLE : obstacles and recommendations for the development of novel treatments’, *Lupus Science and Medicine*, pp. 1–11. doi: 10.1136/lupus-2017-000239.

Touma, Z., Gladman, D. D. and Urowitz, M. B. (2013) ‘Clinical Measures, Metrics, and Indices’, in *Dubois’ Lupus Erythematosus and Related Syndromes: Eighth Edition*. Eighth Edi. Elsevier Inc., pp. 563–581. doi: 10.1016/B978-1-4377-1893-5.00046-7.

Tsai, Y. *et al.* (2014) ‘CD8 + Treg Cells Associated with Decreasing Disease Activity after Intravenous Methylprednisolone Pulse Therapy in Lupus Nephritis with Heavy Proteinuria’, *PLoS ONE*, 9(1), pp. 1–12. doi: 10.1371/journal.pone.0081344.

Tseng, C. E. *et al.* (2006) ‘The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial’, *Arthritis and Rheumatism*, 54(11), pp. 3623–3632. doi: 10.1002/art.22198.

Tsokos, G. C. *et al.* (2016) ‘New insights into the immunopathogenesis of systemic lupus erythematosus’, *Nature Reviews Rheumatology*. Nature Publishing Group, 12(12), pp. 716–730. doi: 10.1038/nrrheum.2016.186.

Vazquez, J. T. *et al.* (2019) ‘Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus’, *Arthritis Rheumatol*, 71(Suppl 10), pp. 1–5.

Vincent, F. B. *et al.* (2014) ‘The BAFF/APRIL system in SLE pathogenesis’, *Nature Reviews Rheumatology*. Nature Publishing Group, 10(6), pp. 365–373. doi: 10.1038/nrrheum.2014.33.

Vincent, F. B. *et al.* (2019) ‘Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus’, 8, pp. 1–11. doi: 10.1002/cti2.1047.

Wardhani, R. and Sufiawati, I. (2018) ‘Oral Manifestations of Systemic Lupus

Erythematous and Its Comprehensive Management: Two Case Reports', *Majalah Kedokteran Bandung*, 50(1), pp. 61–66. doi: 10.15395/mkb.v50n1.1234.

Wenzel, J. (2019) 'Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.', *Nature reviews. Rheumatology*. United States, 15(9), pp. 519–532. doi: 10.1038/s41584-019-0272-0.

Wilkinson, C. *et al.* (2020) 'The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: A post hoc meta-analysis', *Arthritis Research and Therapy*. Arthritis Research & Therapy, 22(1), pp. 1–11. doi: 10.1186/s13075-020-02177-0.

Wong, E. B. *et al.* (2015) 'B Cell–Intrinsic CD84 and Ly108 Maintain Germinal Center B Cell Tolerance', *The Journal of Immunology*, 194(9), pp. 4130–4143. doi: 10.4049/jimmunol.1403023.

Woo, J. M. P. *et al.* (2022) 'The role of environmental exposures and gene – environment interactions in the etiology of systemic lupus erythematosus', pp. 755–778. doi: 10.1111/joim.13448.

Yan, S. *et al.* (2015) 'Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL / MpSlac-lpr mice', *Nature Publishing Group*. Nature Publishing Group, 36(11), pp. 1367–1376. doi: 10.1038/aps.2015.76.

Yoshio, T. *et al.* (2016) 'IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus', *Lupus*, 25(9), pp. 997–1003. doi: 10.1177/0961203316629556.

You, Y. *et al.* (2015) 'Methylprednisolone attenuates lipopolysaccharide-induced Fractalkine expression in kidney of Lupus-prone MRL / lpr mice through the NF-kappaB pathway', *BMC Nephrology*. BMC Nephrology, pp. 1–8. doi: 10.1186/s12882-015-0145-y.

Zahr, Z. A. *et al.* (2013) 'Predictors of corticosteroid tapering in SLE patients: The Hopkins Lupus Cohort', *Lupus*, 22(7), pp. 697–701. doi: 10.1177/0961203313490434.

Zaki, D. S. D. *et al.* (2019) 'Study of B Cell Activating Factor (BAFF) and BAFF-R in Systemic Lupus Erythematosus Patients', 9(6), pp. 203–209. doi: 10.5923/j.ajmms.20190906.06.

Zeher, M. *et al.* (2011) 'Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis', *Lupus*, 20(14), pp. 1484–1493. doi: 10.1177/0961203311418269.

Zeid, M. M. H. *et al.* (2018) 'Study of urinary interferon gamma-induced protein 10 (IP-10) and urinary soluble CD 25 (sCD25) as markers of lupus nephritis and

their relation to histological class', *Alexandria Journal of Medicine*. Alexandria University Faculty of Medicine, 54(4), pp. 647–653. doi: 10.1016/j.ajme.2018.11.001.

Zhang, P. and Lu, Q. (2018) 'Genetic and epigenetic influences on the loss of tolerance in autoimmunity', *Cellular and Molecular Immunology*. Nature Publishing Group, 15(6), pp. 575–585. doi: 10.1038/cmi.2017.137.

Zhang, R. *et al.* (2019) 'Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus', *Experimental and Therapeutic Medicine*, 18, pp. 4067–4075. doi: 10.3892/etm.2019.8013.

Zollars, E. *et al.* (2015) 'BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year', *Lupus Science and Medicine*, 2(1), pp. 1–7. doi: 10.1136/lupus-2014-000063.